These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 5034697)

  • 1. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A; Mars H; Botez MI; Joubert M
    Can Med Assoc J; 1972 Jun; 106(11):1169-74. PubMed ID: 5034697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A; Gillo-Joffroy L; Mars H; Arsenault A
    Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 4. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
    Dupont E; Hansen E; Melsens S; Parkenberg H; Holm P
    Acta Neurol Scand Suppl; 1972; 51():115-7. PubMed ID: 4514334
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
    Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
    No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic uses and side effects of L-dopa.
    Boshes B
    Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081
    [No Abstract]   [Full Text] [Related]  

  • 11. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
    Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
    [No Abstract]   [Full Text] [Related]  

  • 12. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 14. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J
    Rev Neurol (Paris); 1970 Apr; 122(4):243-8. PubMed ID: 5472041
    [No Abstract]   [Full Text] [Related]  

  • 15. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 16. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 17. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL; Ringel SP
    Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 19. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa and related drugs.
    Med Lett Drugs Ther; 1973 Mar; 15(5):21-3. PubMed ID: 4697470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.